Biomerica, Inc.
BMRA · NASDAQ
Market closed$1.61$-0.016100 (-0.99%)After hours $1.61 · -0.24%
Key statistics
Previous close$1.63
Open$1.63
Day high$1.63
Day low$1.61
52-week high$4.60
52-week low$1.61
Market cap4.99M
Volume3.96K
Average volume15.18K
P/E ratio-1.18
Forward P/E—
EPS-1.37
Dividend yield0.00%
Market context
Why it moved
BMRA's modest decline today appears to reflect routine market selling pressure amid low trading volume, with no significant company-specific news identified as a catalyst for the move.
What is happening
Recent company-specific developments and publisher coverage.
Investing.com · May 28, 2026Biomerica signs contract development deal worth over $1.75MOrange County Business Journal · May 28, 2026Biomerica Wins $1.75M Contract to Develop Diagnostic TestsPluang · April 29, 2026Biomerica's inFoods® IBS diagnostic therapy dat...Quiver Quantitative · April 16, 2026Biomerica, Inc. Receives Medicare Confirmation for inFoods® IBS Claims Processing PathwayPluang · April 14, 2026Biomerica launches inFoods® IBS diagnostic plat...qz.com · January 14, 2025Biomerica Inc. (BMRA) reports earnings Benzinga · April 16, 2026Biomerica's Ethos Laboratories' Test Now Eligible For Medicare Coverage On Individual Basis Announced By Medicare Administrative Contractor Benzinga · April 14, 2026Biomerica Q3 EPS $(0.44) Up From $(0.48) YoY, Sales $987.000K Down From $1.119M YoY Benzinga · March 18, 2026Biomerica Receives First Commercial Order For Hp Detect, Helicobacter Pylori Diagnostic Stool Antigen Test Benzinga · February 26, 2026Biomerica Announces Responder Analysis Results From Ongoing Real-World Study Of inFoods IBS Benzinga · December 23, 2025Biomerica Says CMS Issues Final Pricing Determination For inFoods IBS Test, Establishing National Medicare Payment Rate Of $300 Under CLFS Benzinga · November 25, 2025Biomerica Highlights Clinical Trial Showing inFoods IBS Test Significantly Reduces Symptoms Through Guided Dietary Therapy In The Fall 2025 Issue Of Biotherapeutics Quarterly, A Henry Schein Publication Mt Newswire · October 16, 2025Biomerica Says Irritable Bowel Syndrome Test to be Marketed by Henry Schein in US Benzinga · September 3, 2025BMRA stock has given up its prior gain. Biomerica shares were trading higher after the UAE Ministry of Health and Prevention approved the company's Fortel Kidney Test for home use.